Table 1. Clinical-Pathologic and Radiologic Characteristics of 90 Patients.

Characteristics		Total (n = 90)
Mean age, years (range)		57 (38–84)
Sex, male:female		69:21
No. of treated HCCs per patient
	1	76 (84.4)
	2	13 (14.4)
	3	1 (1.2)
Risk factors
	Hepatitis B	67 (74.4)
	Hepatitis C	8 (8.9)
	Alcoholic liver disease	6 (6.7)
	Hepatitis B and alcoholic liver disease	4 (4.4)
	Hepatitis C and alcoholic liver disease	1 (1.1)
	Cryptogenic liver cirrhosis	4 (4.4)
Child-Pugh classification
	A	82 (91.1)
	B	8 (8.9)
Median serum AFP (range), ng/mL		16.9 (1.6–30741.3)
Pretreatment LI-RADS category*
	LI-RADS 4	15 (14.3)
	LI-RADS 5	82 (78.0)
	LI-RADS M	1 (1.0)
	LI-RADS TIV	7 (6.7)
Type of locoregional treatment*
	Conventional TACE	60 (57.0)
	RFA	25 (23.8)
	TACE + RFA	13 (12.4)
	DEB - TACE	3 (2.9)
	TARE	2 (1.9)
	PEA	1 (1.0)
	DEB - TACE + RFA	1 (1.0)
Type of surgery
	Surgical resection	35 (38.9)
	Living donor liver transplantation	50 (55.6)
	Deceased donor liver transplantation	5 (5.6)
Histopathologic necrosis, %†
	0	1 (1.0)
	1–50	26 (26.3)
	51–99	40 (40.4)
	100% (pathologically nonviable)	32 (32.3)
Signal intensity on precontrast T1-WI*
	Iso- or hypointensity	65 (61.9)
	Hyperintensity	40 (38.1)

Data are number (%) of patients unless specified otherwise. ^*Data are number (%) of lesions out of a total number of 105 lesions, ^†Six lesions were pathologically confirmed as viable HCC, but degree of necrosis was not reported in pathologic report. AFp = alpha-fetoprotein, DEB = drug-eluting beads, HCC = hepatocellular carcinoma, LI-RADS = Liver Imaging Reporting and Data System, PEA = percutaneous ethanol ablation, RFA = radiofrequency ablation, TACE = transarterial chemoembolization, TARE = transarterial radioembolization, TIV = tumor-in-vein, T1-WI = T1-weighted imaging